|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,010 JPY | +5.12% |
|
+10.45% | +29.39% |
| Apr. 25 | Scholz pledges further support for the pharmaceutical industry | DP |
| Apr. 25 | Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024 | MT |
March 23 (Reuters) - Daiichi Sankyo Co Ltd:
* STARTED FIRST VACCINATIONS IN A PHASE 1/2 CLINICAL TRIAL IN JAPAN OF AN MRNA COVID-19 VACCINE BEING DEVELOPED BY CO Source text : (https://bit.ly/3tKwxfH) Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| +29.39% | 58.76B | |
| +25.75% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +2.93% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.28% | 144B |
DAIICHI SANKYO CO., LTD. 
